TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM821061

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL
RESUBMIT DOCUMENT ID:	900780976

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
PEAR THERAPEUTICS (US), INC.		06/16/2023	Corporation: DELAWARE
PEAR THERAPEUTICS, INC.		06/16/2023	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	HARVEST BIO LLC
Street Address:	135 SEAPORT BLVD., UNIT 1106
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02210
Entity Type:	Limited Liability Company: DELAWARE

PROPERTY NUMBERS Total: 3

Property Type	Number	Word Mark
Serial Number:	97372560	EFORMULATION
Serial Number:	87289058	
Serial Number:	87289040	PEAR THERAPEUTICS

CORRESPONDENCE DATA

Fax Number: 4153742399

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4153742300


Email: teri.nelmark@hoganlovells.com **Correspondent Name:** HOGAN LOVELLS US LLP

Address Line 1: Four Embarcadero Center, Suite 3500 Address Line 4: San Francisco, CALIFORNIA 94111

NAME OF SUBMITTER: JASON LOHR **SIGNATURE:** /Jason Lohr/ **DATE SIGNED:** 06/30/2023

Total Attachments: 19

source=Pear - Harvest Bio - IP Assignment Agreement (003)#page1.tif



INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this "Assignment") is effective as of June 16, 2023, and is made and entered into between PEAR THERAPEUTICS (US), INC., a Delaware corporation ("Pear Therapeutics (US)") and PEAR THERAPEUTICS, INC., a Delaware corporation which owns 100% of the issued and outstanding capital stock of Pear Therapeutics US ("Parent"; Parent together with Pear Therapeutics (US), the "Assignor"), and HARVEST BIO LLC, a Delaware limited liability company ("Assignee"), pursuant to the Asset Purchase Agreement dated as of May 21, 2023 (the "Purchase Agreement"), by and among the Assignor and Assignee. Capitalized terms used in this Assignment without definition shall have the respective meanings given to them in the Purchase Agreement, and Section 9.6(a) of the Purchase Agreement (Certain Interpretations) applies to this Assignment.

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement and subject to the terms and conditions therein, Assignor and Assignee agree as follows:

- 1. Assignor hereby irrevocably assigns, transfers and conveys to Assignee, any and all of its right, title and interest in and to all Seller Owned Intellectual Property, including each item of Intellectual Property set forth on Schedule A hereto, held or used in the conduct of, or which in any way, directly or indirectly, comprise or relate to, or are necessary or useful for the further research, development and commercialization of, the Business related to the Acquired Assets, including all goodwill appurtenant thereto, all rights therein provided by international conventions and treaties, all rights of priority and renewals, and all rights to sue and recover damages for past, present and future infringement, dilution, misappropriation or other violation thereof, whether such rights are registered or not, and all rights of priority therein, and the right to recover for damages and profits and all other remedies for past infringements thereof, and any and all appurtenant goodwill associated therewith, but excluding any Excluded Assets. In accordance with Section 2.8 of the Purchase Agreement, the Intellectual Property included in the Acquired Assets shall include:
 - (a) the Intellectual Property set forth on Exhibit A to the Purchase Agreement and all other Intellectual Property related to or used in connection with any Acquired Assets, plus:
 - (b) all reissues, reexaminations, divisions, renewals, extensions, provisionals, continuations, continuations-in-part, and domestic and foreign counterparts of any of the patents or patent applications described in clause "(a)" above, all other patents and patent applications that derive or may derive a claim of priority from any of the patents or patent applications described in clause "(a)" above, and each patent issuing on any of the foregoing;
 - (c) each patent and patent application that is referenced by a terminal disclaimer filed in connection with any of the patents or patent applications identified in clause "(a)" or clause "(b)" above;
 - (d) all subject matter, and each invention, claimed or disclosed in each of the patents and patent applications described in "(a)", "(b)", or "(c)" above;
 - (e) all rights to apply in any and all jurisdictions anywhere in the world for patents, certificates of inventions, utility models, or other governmental grants with respect to each patent, patent application, and invention described above, including the right to apply for patents pursuant to any convention, treaty, agreement or understanding; and

- (f) any and all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and other enforcement rights under, or on account of, any of the foregoing Intellectual Property, including all causes of action and other enforcement rights for (1) damages, (2) injunctive relief, (3) any other remedies of any kind (in each of the cases in clauses "(1)", "(2)", and "(3)" of this paragraph for past, current, and future infringement), and (4) all rights to collect royalties and other payments under or on account of each of the foregoing Intellectual Property.
- 2. Upon and at any time after the Closing, at Assignee's request, Assignor shall, without further consideration, execute and deliver to Assignee such other instruments and documents, and take such other actions as Assignee may reasonably deem necessary or desirable to effect, evidence, record and perfect the transfer and assignment contemplated by this Assignment. In the event that Assignor fails to execute and deliver such instruments and documents, Assignor hereby authorizes and appoints Assignee and Assignee's authorized representatives as Assignor's true and lawful attorney in fact solely for the purposes of executing and delivering such instruments and documents on behalf of and in the name of Assignor as to effect, evidence or perfect the transfer and assignment of the Acquired Assets to Assignee, including any filings with the United States Patent and Trademark Office, United States Copyright Office or any similar or corresponding entities or agencies in all other jurisdictions.
- 3. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.
- 4. This Agreement shall be governed by, interpreted under, and construed and enforceable in accordance with, the laws of the State of Delaware, without regard to its conflict of law principle provisions and rules.
- 5. To the extent this Agreement is inconsistent with any terms or conditions in the Purchase Agreement, the Purchase Agreement shall control.
- 6. This Agreement may be executed in counterpart signature pages, all of which when so executed and attached hereto shall constitute one and the same original.

[Signature pages follow.]

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNOR:

PEAR THERAPEUTICS (US), INC.

Christopher D. T. Guiffre

1103AC691A1E466...
Name: Christopher D. T. Guiffre

Title: Chief Financial Officer & Chief Operating

Officer

PEAR THERAPEUTICS, INC.

~DocuSigned by: Christopher D. T. Guiffre

Name: Christopher D. T. Guiffre

Title: Chief Financial Officer & Chief Operating

Officer

IN WITNESS WHEREOF, the parties hereto have executed this Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNEE:

HARVEST BIO LLC --- DocuSigned by:

By: (ory McCann
Name: Corey McCann

Title: Manager

Schedule A Patents

Domestic & Foreign Patents Indication Owner	atents Owner	Title Patent #	# Serial #	Status	Country ID Type Filed Date Publication #	Type Filed	Date Publi		Issue Date
enia	+ NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	2.0198E+11	PUBLISHED	CN	UTL 6/21/	6/21/2019 11359		~~~~
Schizophrenia [Pear[11] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	PCT/US2019/0384€NA	NAT PHASE WO		UTL 6/21/2019	2019		
Schizophrenia [Pear[12] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	2019374695	PENDING	AU	UTL 6/21/2019	2019		
Schizophrenia I	Pear[14] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	3118712	PENDING	CA	UTL 6/21/2019	2019		
Schizophrenia [Pear[15] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	19740132.6	PUBLISHED	EP	UTL 6/21/2019	/2019 3877982	982	
Schizophrenia [Pear[16] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	2021-525324	PENDING	JP	UTL 6/21/2019	′2019		
Schizophrenia [Pear[17] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	282965	PUBLISHED	IL	UTL 6/21/2019	/2019 44348	∞	
Schizophrenia [Pear[18] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	10-2021-7017059	PUBLISHED	KR	UTL 6/21/2019		10-2021-0111750	
Schizophrenia <u>I</u>	Pear[19] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	776081	PENDING	NZ	UTL 6/21/2019	2019		
Schizophrenia [Pear[20] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	11202104754P	PENDING	SG	UTL 6/21/2019	2019		
Schizophrenia <u>I</u>	Pear[22] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	62/757,077	EXPIRED	SN	PRV 11/7/2018	/2018		
Schizophrenia I	Pear[24] + NIBR	Electronic Devices and Methods for Treatment Utilizing Antipsychotics in Combination with Digital Therapies	16/448,907	PUBLISHED	US	UTL 6/21/	6/21/2019 20200143931	0143931	
[2] Patent is jointly owned with NIBR. [11] Patent is jointly owned with NIBR. [12] Patent is jointly owned with NIBR. [14] Patent is jointly owned with NIBR. [15] Patent is jointly owned with NIBR. [15] Patent is jointly owned with NIBR. [17] Patent is jointly owned with NIBR. [18] Patent is jointly owned with NIBR. [19] Patent is jointly owned with NIBR. [20] Patent is jointly owned with NIBR. [21] Patent is jointly owned with NIBR.		2) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.1) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.2) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.3) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.6) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.7) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.8) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly owned with NIBR. Purchaser will receive Pear's interest in patent to be jointly owned with NIBR. 1.9) Patent is jointly o	with NIBR. h NIBR.						

Statistic Association Statistica Scott Statistic Scott Statistic Scott Statistic Scott Statistic Statist	rense Agreeotents		Ontant Tyre	888							
Control Cont	ense Agreements		Content Type Contract								
Part	maetic and Fareign Pa	SAMES.									
Coloniary Colo	Nuner (ESS)		Patent	16/985,807	ABANDONED	Country II I y		Dat	3/5/2020	20200384198	
Michael August 1000 Control Contro	728		0572629	15/265,016	BSUED	us	S		_		2/25/2020
Martings and 1911 for San Ancidents	220		0786626	15/349,974	ISSUED	Su	S				9/29/2020
CONTINUE AND PRINTING OF AN ALCORATION CONTINUE AND ALCORATION C	3520	METHODS AND SYSTEMS FOR MODIFYING		15/044,470	ABANDONED	Su	S		_	20160199577	
Marchine And 1974 1	100	SYSTEMS AND APPARATUS FOR MEASURING A		15/395,777	ABANDONED	US.	S			20170231560	
Contention Con	EIS!	METHODS AND SYSTEMS FOR MODIFYING		16/935,588	ABANDONED	S	S		7/22/2020		
Companion For Prince	SECO.	METHODS AND SYSTEMS FOR PRESENTING A		14/853,726	ABANDONED	us	S		$\overline{}$	20160074583	
Combined And Systems Presenting A.	E		064036	12/217,509	ISSUED.	us	S		7/3/2008		5/23/2015
Combination Transmit Modification Anthonics Binistelli Modification Combination Transmit Modification Anthonics Binistelli Modification Combination Transmit Modification And Printing Modification Combination Co	2022		026369	12/290,456	ISSUED	us	S			US2009/0271219	5/5/2015
Combination Instituted Advances Address Ad	RECOR	- 1	876688	12/157,160	ISSUED	us	S		3/6/2008		11/4/2014
Combination Transmister Advantation And Processing 100-2002 107-106-201 107-10	RIG		974787	12/154,275	ISSUED.	us	S		9/21/2008		7/5/2011
International Acquisitions International Acquisitional Acquisitions International Acquisitional Acquisit	75031	tion Treatment Alteration Methods And	801686	12/214,547	ISSUED	S	S	_	5/19/2008		9/21/2010
Application of Spacemin for Descring A Rescribe (60 Section 10 S	RECO	And Systems For Monitoring Bioactive	606592	12/217,620	ISSUED.	us	S		7/7/2008		12/10/2013
Principle Prin	ELLE	Methods And Systems For Detecting A Bioactive 8	615407	12/283,742	ISSUED	us	S		3/15/2008		12/24/2013
Continued Treatment	15 CAN		930208	12/283,619	ISSUED	Sn	S		3/12/2008		1/6/2015
Column and Apperatus for Neutrining A	ETE.	For Presenting A	582587	12/315,072	ISSUED.	Sn	S		11/26/2008		3/25/2014
Paper Dec.	100E		560967	12/220,706	gsusa	US.	<u> </u>		7/25/2008		2/1/2017
Sea et first, femiliste and is planner Sea et first, femiliste and is plan	1729	And Systems For Modifying Bloactive e	282927	12,225,531	BSUED	Sn	S	12	3/22/2065	(6)	3/15/2016
Delication Del	1221		662391	12/156.949	gausa		S		3/5/2008		5/30/2017
Part Use	<u> </u>		649469	12/315,366	85UED		S		12/1/2008		5/16/2017
Monte Mont	231	or Modifying Bloactive	504788	13/857,721	BSUED		S		1/5/2013		11/29/2016
Specimen Technological Processor Security Secur	231	ds And Systems For Presenting A :	358567	345,181,781.	GRUSS		S		2/14/2014		6/7/2016
	200		449150	226,251/21	BSUED		5		V13/2008		9/20/2016
Recent are automation. Bill become decrement. If Elikatoria aluminosis konstruired, flowe probabilistic flowe probabilistic flower prob	144		239006	12/384,186/3	PAGE				Sub/2008		0102/61/1
68 Managers subject to 186 Decroe Agreement. 1175 Decroe Agreement's not expured, Desceptions and not be transferred. The base we wish at the 166 Decroe Agreement. 1175 Decroe Agreement's not a surred trace analysis will not be transferred.	BORGEL DE MANAGEN BORGEL DE MAN	ESIALOGIA, ACARRONIA, LEGIALORIA ANI SECONDADANA ESIALOGIA, ACARRONIA, LEGIALORIA ANI SECONDADANA ESIALOGIA, ACARRONIA, LEGIALORIA ANI SECONDADANA ESIALOGIA, ACARRONIA, LEGIALORIA ANI SECONDADA ESIALOGIA, ANI SECONDADA ANI SECONDADA ESIALOGIA ESIALOG	THE STATE OF STATE OF THE STATE	LINER RECOGNOCAL LINER							

Domestic & Foreign Patents	ents								
Indication	Owner	Title	Patent #	Serial#	Status	y ID	Type Fi	led Date F	Type Filed Date Publication #
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scierosis		62/835,250	EXPIRED		PRV 4	4/17/2019	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scierosis		2020257885	PENDING	٤	UTL 4	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scierosis		3136946	PENDING	CA	UTL 4	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scierosis		202080038804	PUBLISHED	CN	UTL 4,	4/13/2020 1	113892147
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		PA 2019 70328	ABANDONED	DK	UTL 5	5/24/2019 F	PA 2019 70328
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Sclerosis		20723703	PUBLISHED	EP	UTL 4	4/13/2020 3	3956905
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scierosis		PCT/US2020/027919	NAT PHASE	WO	UTL 4	4/13/2020 2	2020214523
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated with Multiple Sciencesis		16/847.043	PUBLISHED	S	UTL 4	4/13/2020 2	20200330019
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scienosis		286965	PENDING	F	UTL 4	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scienosis		2021-561930	PUBLISHED	ЪР	JTL &	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scienosis		10-2021-7035667	DAHSHBOA	Š	UTL &	4/13/2020 1	10-2022-0009942
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scienosis		781049	PENDING	Z	UTIL 4	4/13/2020	
MS / Depression	Pear	Electronic Devices and Methods for Treating Depressive Symptoms Associated With Multiple Scienosis		11202111418X	PENDING		UTL 4	4/13/2020	
MS / Depression	Praufil ±	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		3136943	PENDING	\$	UTL 4	4/13/2020	
MS / Depression	Pear(3).*. NIBB	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		202080038801	PUBLISHED	S	UTL 4	4/13/2020 1	114303204
MS / Depression	Pearl41 • NJER			PA 2019 70330	ABANDONED	DK	S TUO	5/24/2019 [DK 2019 70328
MS / Depression	Pearlist.+.			20722200	PUBLISHED	Ę	UTL &	4/13/2020 3	3956899
NS / Depression	सिक्षा इस्टिम्बर्स	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		286964	PENDING	F	UTI A	4/13/2020	
MS / Depression	PeadZl.*.	_		2021-561931	PUBLISHED	ĴР	UTL 4	UTL 4/13/2020 Z	2022-529474
MS / Depression	EearlEL:	_		10-2021-7035660	PUBLISHED	Ş	UTL 4	4/13/2020 1	10-2022-0011118
MS / Depression	स्त्राह्य इस्टाह्य	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		781057	PENDING	Z	UTI.	4/13/2020	
MS / Depression	Pearfful.	Electronic Devices and Methods for Treatment of Depressive Symptoms. Depressive Disorders Utilizing Digital Therapies		11202111417U	PENDING	SG	UTE 4	4/13/2020	
MS / Depression	Ecadail + Niss	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		2020260060	PENDING	Ą	UTL 4	4/13/2020	
MS / Depression	Eseu(21).	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		PCT/US2020/027892	NAT PHASE	WO	OT:	4/13/2020 2	2020214513
MS / Depression	Pearf231	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		62/635,295	EXPIRED	S	PRV 4	4/17/2019	
MS / Depression	Pear(25).	Electronic Devices and Methods for Treatment of Depressive Symptoms, Depressive Disorders Utilizing Digital Therapies		16/846.996	PUBLISHED	ß	J.F.	4/13/2020 2	20200335191
J. Patent is jointly owned (3). Patent is jointly owned (4). Patent is jointly owned (4). Patent is jointly owned (4). Patent is jointly owned (5).	with NIBS. dwith NIBS. dwith NIBS. dwith NIBS.	i i i i i i i i i i i i i i i i i i i	998. 1981. 1982. 1983. 1984. 1984. 1984. 1985. 1985. 1986.						

Daniesiic & Foreign Phrais

Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Pear	Owner Pear
A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	The Ornamental Design for a Display Screen or Portion thereof with an Animated Graphic User Interface	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	Ornamental Design for a Display Screen or Portion Thereof with a Graphical User Interface	The Ornamental Design for a Display Screen or Portion thereof with an Animated Graphic User Interface	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	A Digital Therapeutic Component to Optimize Buprenorphine Induction	Report Your Status Filed as: Graphical User Interface	Therapy Lessons Filed as: Display Screen or Portion Thereof with an Animated Graphical User Interface	DISPLAY SCREEN OR PORTION THEREOF WITH A GRAPHICAL USER INTERFACE Formerly: Graphical User Interface	Title Display Screen or Portion Thereof With an Animated Graphical User Interface
		90063696580004	90063696580003	90063696580002	90063696580001	006369658-0004	006369658-0003	006369658-0002	006369658-0001						D917,501	D899,438	<u>Patent #</u> D880,498
19895058.6	PCT/US2019/066509	90063696580004	90063696580003	90063696580002	90063696580001	006369658-0004	006369658-0003	006369658-0002	006369658-0001	201980091821	3122430	2019396627	62/779,705	29/665,673	29/665,666	29/665,670	<u>Serial #</u> 29/665,681
PUBLISHED	NAT PHASE	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	PUBLISHED	PENDING	PENDING	EXPIRED	ABANDONED	ISSUED	ISSUED	<u>Status</u> ISSUED
EP	WO	GB	GB	GB	GB	EU	EU	EU	EU	CN	CA	AU	US	US	US		Country ID US
UTL	UTL	DES	DES	DES	DES	DES	DES	DES	DES	UTL	UIL	UTL	PRV	DES	DES	DES	<u>Type</u> DES
12/16/2019	12/16/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	12/16/2019	12/16/2019	12/16/2019	12/14/2018	10/5/2018	10/5/2018	10/5/2018	<u>Filed Date</u> 10/5/2018
3895173										113811950						DES 10/5/2018 10/20/2020	Publication#
		4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019	4/4/2019						4/27/2021	10/20/2020	<u>Issue Date</u> 4/7/2020

Pear	Pear	Pear	Pear	Pear	Pear
:	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products		A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	A Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products	Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products
11202106207V	777482 PENDING NZ	10-2021-7020286	2021-533336	283747 PENDING IL	16/715,680
PENDING	PENDING	PUBLISHED	PENDING	PENDING	PUBLISHED
SG	ZZ	KR	JР	I	US
TILN	TIU	TTU	TTU	TIU	UTL
UTL 12/16/2019	UTL 12/16/2019	12/16/2019	UTL 12/16/2019	UTL 12/16/2019	UTL 12/16/2019
	UTL 12/16/2019	UTL 12/16/2019 10-2021-0114940	2021-533336 PENDING JP UTL 12/16/2019	UTL 12/16/2019	20200187777

Trademarks

Corporate Trademarks

COUNTRY	MARK	APP. NO.	REG. NO.	STATUS	GOODS/SERVICES	FILE DATE
United States of America	EFORMULATION	97372560		Published (5/16/23)	09 - Downloadable software for collecting data on a patient's use of and subjective experience with pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for guiding a patient's use of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for monitoring and improving the efficacy of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for monitoring and improving the side effects of pharmaceuticals, nutritional supplements, or medical foods; Downloadable software for collecting biometric data from patients; Downloadable software for the treatment of diseases and disorders	4/20/2022
United States of America	Pear Logo	87289058	5404618	Registered	05 - nutritional supplements	1/4/2017
United States of America	Pear Logo	87289058	5404618	Registered	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	1/4/2017
United States of America	Pear Logo	87289058	5404618	Registered	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements	1/4/2017
United States of America	Pear Therapeutics	87289040	5399391	Registered	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	1/4/2017

	(WIPO)	CANADA		(WIPO)	AUSTRALIA	United States of America	
	THERAPEUTICS	PFAR			PEAR THERAPEUTICS	PEAR THERAPEUTICS	1
		1685744			1685744	87289040	
					1686230	5399391	
	Under examination	PENIDING -			REGISTERED	Registered	
42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements	with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements 100 - Software for collecting data on a nation's use of and subjective experience	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to		09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements	
		8/18/2022			8/18/2022	1/4/2017	
					8/18/2022	2/13/2018	

(WIPO)	ISRAEL		(WIPO)	EUROPEAN UNION (EUTM & RCD)	CHINA	CHINA	CHINA
	PEAR THERAPEUTICS			PEAR THERAPEUTICS	PEAR THERAPEUTICS (refile)	PEAR THERAPEUTICS	PEAR THERAPEUTICS
	1685744			1685744	69383448	67589216	67590987
				1685744			
	Published for opposition: opposition period ends June 1, 2023			REGISTERED	PENDING - Under examination	1/29/23 response filed; supplemental evidence due April 29, 2023.	1/29/23 response filed; supplemental evidence due April 29, 2023.
	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - Clinical trials; Medical laboratory service; Medical research; Scientific research; Research and development of new products for others; Software as a service (SaaS); Computer software installation, maintenance and repair; Mobile phone software design; Electronic data storage; Medical computer programming; Computer software research and development; Computer software design.	42 - 1. medical research: 2. research and development of new products for others; 3. scientific research; 4. software as a service [SaaS]; 5. computer software design; 6. Computer software installation, maintenance and repair; 7. Mobile phone software design; 8. electronic data storage; 9. Medical computer programming; 10. Computer software research and development	09 - 1. computer software, recorded; 2. computer software applications, downloadable; 3. software as a medical device [SaMD], downloadable; 4. data processing apparatus; 5. Smartphone software applications, downloadable; 6. biometric identity cards; 7. Computer programs, downloadable; 8. Computer software for processing digital images; 9. Central processor for processing information, data, sound and images; 10. Software for radiation dose measurement in the field of radiotherapy
	8/18/2022			8/18/2022	2/3/2023	10/8/2022	10/8/2022
				8/18/2023			

(WIPO)	SINGAPORE		(WIPO)	NEW ZEALAND		(WIPO)	JAPAN	
	PEAR THERAPEUTICS			PEAR THERAPEUTICS			PEAR THERAPEUTICS	
	1685744			1685744			1685744	
				1685744				
	PENDING - Under examination			REGISTERED			PENDING - Under examination	
	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - Software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services namely software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services namely software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements.	supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	erience itional ritional	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements		09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements
	8/18/2022			8/18/2022			8/18/2022	
				8/18/2022				

		T		Т
	KINGDOM (WIPO)		SOUTH KOREA (WIPO)	
	PEAR THERAPEUTICS		PEAR THERAPEUTICS	
	1685744		1685744	
	1685744			
	REGISTERED		PENDING - Under examination	
42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements	09 - Software for collecting data on a patient's use of and subjective experience with nutritional supplements; software for guiding a patient's use of nutritional supplements; software for monitoring and improving the efficacy of nutritional supplements; software for monitoring and improving the side effects of nutritional supplements; software for collecting biometric data from patients	42 - software development in the fields of healthcare, therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for monitoring, reporting on, and analyzing the use of therapeutics, pharmaceuticals, and nutritional supplements; software as a service (SAAS) services featuring software for healthcare providers and patients to communicate regarding healthcare and the use of therapeutics, pharmaceuticals, and nutritional supplements
	8/18/2022		8/18/2022	
	8/18/2022			

			Singapore	Zealand and	Korea, New	Japan, S.	UK, Israel,	Canada, EU,	Australia,	designating	WIPO
										THERAPEUTICS	PEAR
											1685744
											1685744
noted above.	countries	the designated	examination in	now under	Application is	2022.	August 18,	Bureau as of	International	with	Registered
							nutritional supplements; software for collecting biometric data from patients	supplements; software for monitoring and improving the side effects of	supplements; software for monitoring and improving the efficacy of nutritional	with nutritional supplements; software for guiding a patient's use of nutritional	09 - Software for collecting data on a patient's use of and subjective experience
											8/18/2022
											8/18/2022

USA	USA	USA	USA	USA	USA	USA	USA	USA	COUNTRY USA	
software as a service (SAAS) services featuring software for the treatment of opioid use disorder, namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with opioid use disorder	software for the treatment of opioid use disorder, namely, software for collecting information and data from and for delivering information and therapy to patients with opioid use disorder	software as a service (SAAS) services featuring software for the treatment of opioid use disorder, namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with opioid use disorder	software for the treatment of opioid use disorder, namely, software for collecting information and data from and for delivering information and therapy to patients with opioid use disorder	software as a service (SAAS) services featuring software for the treatment of alcohol use disorder, namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with alcohol use disorder	software for the treatment of alcohol use disorder, namely, software for collecting information and data from and for delivering information and therapy to patients with alcohol use disorder	software as a service (SAAS) services featuring software for the treatment of substance use disorder, namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with substance use disorder	software for the treatment of substance use disorder, namely, software for collecting information and data from and for delivering information and therapy to patients with substance use disorder	software as a service (SAAS) services featuring software for the treatment of substance use disorder, namely, software for healthcare providers to access and analyze information and data from and to provide information and therapy to patients with substance use disorder	GOODS/SERVICES software for the treatment of substance use disorder	
reSET-O Logo	reSET-O Logo	RESET-O	RESET-O	RESET-A	RESET-A	reSET Logo	reSET Logo	RESET	MARK RESET	
87925189	87925189	87925200	87635226	97139698	97139698	87925174	87925174	87925158	<u>APP. NO.</u> 86802103	
42	9	42	9	42	9	42	9	42	CLASS 9	
			5740689					6190252	<u>REG. NO.</u> 5138595	
5/17/2018	5/17/2018	5/17/2018	10/5/2017	11/23/2021		5/17/2018	5/17/2018	5/17/2018	FILE DATE 10/28/2015	
5/17/2018 Opposed			4/20/2019					11/3/2020	<u>REG DATE</u> 2/7/2017	
Opposed	Opposed	Opposed	Registered (cancellation denied; under appeal)	Pending (Opposed)	Pending (Opposed)	Opposed	Opposed	Registered	STATUS Registered	

Copyrights

Pear Therapeutics, Inc. Pear-004.	Name Full Title	Copyrights _
TX0008935636	Copyright Number	
2020	Date	1

Name
Pear
Therapeutics,
Inc.
Pear
Therapeutics,

RESET 1.7.0 and RESET-O 1.3.0 & 2 other titles

Full Title RESET 1.7.0 and RESET-O 1.3.0

Copyright
Number
TX0008825251

<u>Date</u> 2019

Pear Therapeutics, Inc.

Pear-008.

TX0008935634

2020

V9978D306

RECORDED: 06/22/2023